MicroRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2

Wu,Yigao; Wang,Wei; Hu,Weilie; Xu,Wenqing; Xiao,Ge; Nie,Qiwei; Ouyang,Keyu; Chen,Shuai

doi:10.3892/or.2015.4295

MicroRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2

Authors:
- Yigao Wu
- Wei Wang
- Weilie Hu
- Wenqing Xu
- Ge Xiao
- Qiwei Nie
- Keyu Ouyang
- Shuai Chen
View Affiliations

Affiliations: Department of Urology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, P.R. China
Published online on: September 21, 2015 https://doi.org/10.3892/or.2015.4295
Pages: 3104-3110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Compared to adrenocortical adenoma (ACA), adrenocortical carcinoma (ACC) has very poor prognosis and limited treatment options. Also conventional methods to distinguish ACC from ACA can be difficult. At this time, no molecular pathological markers are reliable enough to distinguish either tumor. Recently, increasing data have indicated miRNAs to be crucial regulators in the tumor‑related processes. In the present study, we found that miR-205 expression is significantly suppressed in ACC tissues compared with ACAs, and that this induces apoptosis and impairs proliferation of ACC SW-13 cells in vitro as well as inhibits tumor growth in vivo. Using bioinformatic predictions, Bcl-2 was identified to be a target of miR-205 via 3'-untranslated region (3'UTR) interactions, which was confirmed by luciferase assay, qRT-PCR, immunohistochemical assay and western blotting showing that mRNA and protein expression of Bcl-2 were negatively related to miR-205. Further investigation into the mechanism found that activation of Bcl-2 cleaved Bax, releasing caspase-9 and -3 that are involved in the intrinsic apoptosis pathway, eventually inducing SW-13 cell apoptosis. In conclusion, miR-205 suppresses the growth of ACC SW-13 cells via targeting the anti-apoptotic gene Bcl-2.

View Figures

View References

1	Lehmann T and Wrzesinski T: The molecular basis of adrenocortical cancer. Cancer Genet. 205:131–137. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E and Sturgeon C: Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer. 113:3130–3136. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kutikov A, Mallin K, Canter D, Wong YN and Uzzo RG: Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: Analysis of the National Cancer Database. J Urol. 186:805–810. 2011. View Article : Google Scholar : PubMed/NCBI
4	Patterson EE, Holloway AK, Weng J, Fojo T and Kebebew E: MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 117:1630–1639. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chiodini I: Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 96:1223–1236. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kuruba R and Gallagher SF: Current management of adrenal tumors. Curr Opin Oncol. 20:34–46. 2008. View Article : Google Scholar
7	Maas S: Gene regulation through RNA editing. Discov Med. 10:379–386. 2010.PubMed/NCBI
8	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
9	Etheridge A, Lee I, Hood L, Galas D and Wang K: Extracellular microRNA: A new source of biomarkers. Mutat Res. 717:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
10	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ferracin M, Veronese A and Negrini M: Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 10:297–308. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al: Serum microRNAs are promising novel biomarkers. PLoS One. 3:e31482008. View Article : Google Scholar : PubMed/NCBI
13	Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
14	Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M and Leteurtre E: Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 26:1612–1619. 2002. View Article : Google Scholar : PubMed/NCBI
15	Jiang B, Li Z, Zhang W, Wang H, Zhi X, Feng J, Chen Z, Zhu Y, Yang L, Xu H, et al: miR-874 inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar
16	Chehrehasa F, Meedeniya AC, Dwyer P, Abrahamsen G and Mackay-Sim A: EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J Neurosci Methods. 177:122–130. 2009. View Article : Google Scholar
17	Skommer J, Brittain T and Raychaudhuri S: Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis. 15:1223–1233. 2010. View Article : Google Scholar : PubMed/NCBI
18	Suzuki H, Maruyama R, Yamamoto E and Kai M: DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 6:567–578. 2012. View Article : Google Scholar : PubMed/NCBI
19	Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, et al: miR-195 and miR-483–5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
21	Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L and Fassan M: Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 25:86–99. 2012. View Article : Google Scholar
22	Greene SB, Herschkowitz JI and Rosen JM: The ups and downs of miR-205: Identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 7:300–304. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yu J, Ryan DG, Getsios S, Oliveira-Fernandes M, Fatima A and Lavker RM: MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci USA. 105:19300–19305. 2008. View Article : Google Scholar : PubMed/NCBI
24	Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E: microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, et al: miR-205 exerts tumor-suppressive functions in human prostate through downregulation of protein kinase Cepsilon. Cancer Res. 69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
27	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
28	Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, Noldus J, Tannapfel A and Mirmohammadsadegh A: MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 43:307–314. 2013.PubMed/NCBI
29	Mesiano S and Jaffe RB: Role of growth factors in the developmental regulation of the human fetal adrenal cortex. Steroids. 62:62–72. 1997. View Article : Google Scholar : PubMed/NCBI
30	West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D, Lalli E, Ribeiro R, et al: Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 67:600–608. 2007. View Article : Google Scholar : PubMed/NCBI
31	Spencer SJ, Mesiano S, Lee JY and Jaffe RB: Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: Implications for growth and remodeling. J Clin Endocrinol Metab. 84:1110–1115. 1999.PubMed/NCBI
32	Coulter CLL: Fetal adrenal development: Insight gained from adrenal tumors. Trends Endocrinol Metab. 16:235–242. 2005. View Article : Google Scholar : PubMed/NCBI
33	El Wakil A, Doghman M, Latre De Late P, Zambetti GP, Figueiredo BC and Lalli E: Genetics and genomics of childhood adrenocortical tumors. Mol Cell Endocrinol. 336:169–173. 2011. View Article : Google Scholar
34	Plati J, Bucur O and Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integr Biol Camb. 3:279–296. 2011. View Article : Google Scholar : PubMed/NCBI
35	Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Åkerström G, Westin G, Lifton RP, Björklund P, et al: Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer. 51:949–960. 2012. View Article : Google Scholar : PubMed/NCBI
36	Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
37	Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 18:1702–1710. 2011. View Article : Google Scholar : PubMed/NCBI
38	Zhu W, Shan X, Wang T, Shu Y and Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI